Efficacy

Tagrisso (Osimertinib) Efficacy in Lung Cancer

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Clinical trials have demonstrated that osimertinib is particularly effective in patients with NSCLC harboring EGFR T790M mutations, which are a common mechanism of resistance to earlier-generation EGFR TKIs. In the AURA3 study, osimertinib significantly improved progression-free survival (PFS) compared to platinum-based chemotherapy in patients with T790M mutation-positive NSCLC who had progressed after first-line EGFR TKI therapy.

Moreover, the FLAURA trial established osimertinib as a first-line treatment option for NSCLC patients with EGFR mutations (exon 19 deletions or exon 21 L858R mutations). In this study, osimertinib not only improved PFS but also showed a survival benefit compared to first-generation EGFR TKIs. The efficacy of osimertinib in improving overall survival highlights its role as a preferred treatment for patients with advanced EGFR-mutated NSCLC.

Rybrevant (Amivantamab-vmjw) Efficacy in Lung Cancer

Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets both the EGFR and MET receptors and has been approved for the treatment of adults with NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. This approval was based on the results of the CHRYSALIS study, which demonstrated that amivantamab-vmjw led to a significant clinical response in a population of patients with few treatment options.

The CHRYSALIS trial showed that amivantamab-vmjw had a manageable safety profile and provided durable responses in patients with NSCLC harboring EGFR exon 20 insertion mutations. The efficacy of Rybrevant in this patient population is particularly noteworthy as these mutations are typically resistant to conventional EGFR TKIs, and patients have limited treatment options. The introduction of amivantamab-vmjw offers a new therapeutic avenue for these patients, with the potential to improve outcomes in a challenging subset of lung cancer.